Gelonghui, April 11 | Jin Dawei (002626.SZ) announced that the company's holding subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd., the company and its wholly-owned subsidiary Inner Mongolia Jindaway Pharmaceutical Co., Ltd., and its wholly-owned subsidiary Jindaway Biotechnology (Jiangsu) Co., Ltd. recently each received an invention patent certificate issued by the State Intellectual Property Office, which is a preparation method for nicotinamide adenine dinucleotide.
金达威(002626.SZ)：“一种烟酰胺腺嘌呤二核苷酸的制备方法”获发明专利
Jin Dawei (002626.SZ): “A method for preparing nicotinamide adenine dinucleotide” obtained an invention patent
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.